Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

A Single Atom Makes A Big Difference To Purer Water
By substituting a single atom in a molecule widely used to purify water, researchers at Sandia National Laboratories have created a far more effective decontaminant with a shelf life superior to products currently on the market.

New York City Labor Unions Agree To Reductions In Health Benefits
"Mayor Michael R. Bloomberg and city labor officials announced a tentative agreement Tuesday to amend health benefits for more than 550,000 current and retired city employees, guaranteeing the city $400 million in savings over the next two fiscal years," The New York Times reports. The arrangement imposes "$50 to $100 co-payments for about one-fifth of current and retired city employees, and eliminates coverage for preventive dental care at certain offices." The paper adds, "For most other city employees, the plan would restrict certain hospital, ambulatory and hemodialysis coverage to network providers and would implement several other administrative cost-saving measures." The agreement requires union approval.
News of the day
Health And Safety Executive Warns Of Dangers In Failing To Maintain Plant Equipment After Driver's Death, UK
The Health and Safety Executive has warned of the danger of not maintaining plant equipment after the death of a telescopic forklift truck driver, who was crushed between the descending arm and side of his vehicle.
Public Health

Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect On Photoreceptors

Neurotech Pharmaceuticals, Inc. announced that the Company"s product candidate, NT-501, demonstrated a strong biologic effect in two Phase 2 clinical trials for retinitis pigmentosa (RP). RP is a slowly developing condition that causes the progressive degeneration of rod & cone photoreceptor cells in the retina that over time diminishes night and peripheral vision and eventually leads to blindness. RP is an orphan-designated indication for which there are currently no approved treatments. In both studies, there was a statistically significant (pAbout Retinitis Pigmentosa (RP) Retinitis Pigmentosa (RP) is an inherited disease that causes the retina"s rod and cone photoreceptors to gradually degenerate leading to loss of vision and blindness. The symptoms of RP predominately appear in young adults and affect approximately 100,000 people in the United States and over 1 million people worldwide. At this time there is no known cure or effective treatment for RP. About NT-501 Neurotech"s lead product, NT-501, consists of encapsulated human cells genetically modified to secrete ciliary neurotrophic factor (CNTF). CNTF is a growth factor capable of rescuing dying photoreceptors and protecting them from degeneration. NT-501 is designed to continually deliver a therapeutic dose of CNTF into the back of the eye. About Encapsulated Cell Technology Neurotech"s core technology platform is Encapsulated Cell Technology (ECT), a unique technology that allows for the long-term, sustained delivery of therapeutic factors to the back of the eye. ECT implants consist of cells that have been genetically modified to produce a specific therapeutic protein and are encapsulated in a semi-permeable hollow fiber membrane. The diffusive characteristics of the hollow fiber membrane are designed to promote long-term cell survival by allowing the influx of oxygen and nutrients while simultaneously preventing direct contact of the encapsulated cells with the cellular and molecular elements of the immune system. The cells continuously produce the therapeutic protein which diffuses out of the implant at the target site. ECT thereby enables the controlled, continuous delivery of therapeutic factors directly to the retina, bypassing the blood-retina barrier. About Neurotech Pharmaceuticals, Inc. Neurotech is developing sight-saving therapeutics for the treatment of chronic retinal diseases. The Company"s lead product candidate, NT-501, is currently in late-stage clinical development for advanced dry age-related macular degeneration (dry AMD) and retinitis pigmentosa (RP). The Company"s portfolio of product candidates also includes treatments for wet AMD. All of Neurotech"s development programs are based on the Company"s proprietary Encapsulated Cell Technology (ECT). ECT uniquely enables the controlled, continuous delivery of biologics directly to the back of the eye, thereby overcoming a major obstacle in the treatment of retinal disease. Neurotech Pharmaceuticals, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009